Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 925-930

  Lin, Chin Chung ^a,b   Xu, Christine ^a   Zhu, Nanqun ^a   Lourenco, David ^a   Yeh, Li Tain ^a  

^a Valeant Research and Development   (United States)

^b Valeant Pharmaceuticals International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CARBON 14; CYTOCHROME P450 3A4; DRUG METABOLITE; PRODRUG; REMOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HEPATITIS B VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; URINARY EXCRETION;

ADENINE; ANIMALS; AREA UNDER CURVE; CARBON RADIOISOTOPES; HALF-LIFE; MACACA FASCICULARIS; MALE; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 14744270508     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.925-930.2005     Document Type: Article

References (11)

1. Cerny, J., S. A. Foster, and Y. Cheng. 1992. Cell-protecting effect against herpes simplex virus-1 and cellular metabolism of 9-(2- phosphonylmethoxyethyl)adenine in HeLa S3 cells. Mol. Pharmacol. 42:537-544.
2. Cundy, K. C., J. P. Shaw, and W. Lee. 1994. Oral, subcutaneous and intramuscular bioavailability of the antiviral nucleotide analog 9-(2-phosphonylmethoxy-ethyl)adenine (PMEA) in cynomolgus monkeys. Antimicrob. Agents Chemother. 38:365-368.
3. Cundy, K. C., P. Barditch-Crovo, R. E. Walker, A. C. Collier, D. Ebeling, J. Toole, and H. S. Jaffe. 1995. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type I-infected patients. Antimicrob. Agents Chemother. 39:2401-2405.
4. Food and Drug Administration. 2002. FDA advisory committee brief document, NDA 21-449. July 5, 2002. Adefovir dipivoxil for the treatment of chronic hepatitis B. Food and Drug Administration, Washington, D.C.
5. Heijtink, R. A., G. A. De Wilde, J. Krunining, L. Berk, J. Balzarini, E. de Clercq, A. Holy, and S. W. Schalm. 1993. Inhibitory effect of 9-2-phosphonylmethoxyethyladenine (PMEA) on human and duck hepatitis B virus infection. Antivir. Res. 21:141-142.
6. Heijtink, R. A., J. Kruining, G. A. de Wilde, J. Balzarini, E. de Clercq, and S. W. Schalm. 1994. Inhibitory effect of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
7. Lin, C., L. Yeh, D. Vitarella, Z. Hong, and M. Erion. 2004. Remofovir mesylate, a prodrug of PMEA, shows good liver-targeting property and safety profiles in animal. Antivir. Chem. Chemother. 15:305-314.
8. Marcellin, P., T. Chang, S. Lim, M. Tong, W. Sievert, M. Shiffman, L. Jeffers, Z. Goodman, M. Wulfsohn, S. Xiong, J. Fry, and C. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
9. Merta, A., J. Vesely, I. Votruba, I. Rosenberg, and A. Holy. 1990. Phosphorylation of acyclic nucleotide analogues HPMPA and PMEA in L1210 mouse leukemic cell extracts. Neoplasma 37:111-120.
10. Palu, S. S., M. Ras, C. Parolin, J. Balzarini, and E. De Clercq. 1991. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antimicrob. Agents Chemother. 16:115-119.
11. Starrett, J. E., M. M. Mansuri, J. C. Martin, D. R. Tortolani, and J. J. Bronson. April 1992. European patent 481, 214, A1.